Aquestive Therapeutics (AQST) Receivables - Other (2017 - 2026)

Aquestive Therapeutics' Receivables - Other history runs 10 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 123.54% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (up 123.54% YoY), while the FY2025 annual figure was $9.8 million, up 294.26% from the prior year.
• Receivables - Other was $1.6 million for Q1 2026 at Aquestive Therapeutics, down from $9.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $9.8 million in Q4 2025 to a low of $601000.0 in Q2 2024.
• Historically, Receivables - Other has averaged $2.4 million across 5 years, with a median of $2.1 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other sank 72.33% in 2024, then jumped 294.26% in 2025.
• A 5-year view of Receivables - Other shows it stood at $2.1 million in 2022, then surged by 36.28% to $2.9 million in 2023, then declined by 15.16% to $2.5 million in 2024, then surged by 294.26% to $9.8 million in 2025, then plunged by 83.54% to $1.6 million in 2026.
• The last three Receivables - Other figures came in at $1.6 million (Q1 2026), $9.8 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.